ARS Pharmaceuticals, Inc. SPRY
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 48.40% | -19.25% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 48.40% | -19.25% | |||
| Cost of Revenue | 65.17% | 10.68% | |||
| Gross Profit | 33.63% | -34.78% | |||
| SG&A Expenses | 7.44% | 20.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.85% | 19.09% | |||
| Operating Income | -2.19% | -45.05% | |||
| Income Before Tax | -2.84% | -46.41% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.84% | -46.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.84% | -46.69% | |||
| EBIT | -2.19% | -45.05% | |||
| EBITDA | -2.18% | -45.56% | |||
| EPS Basic | -2.82% | -46.30% | |||
| Normalized Basic EPS | -2.83% | -63.87% | |||
| EPS Diluted | -2.82% | -45.57% | |||
| Normalized Diluted EPS | -2.83% | -63.87% | |||
| Average Basic Shares Outstanding | 0.02% | 0.27% | |||
| Average Diluted Shares Outstanding | 0.02% | 0.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||